Farmak JSC, the leading manufacturer of neurological and endocrinologic drugs in Ukraine, has developed and launched on the market a new antiepileptic drug, Meditan® (active ingredient: gabapentin) that comes in capsules.
Meditan® is intended for treatment of partial epileptic seizures with or without secondary generalization in adults and children (in combination with other antiepileptic drugs for children over 6 or as a monotherapy for children over 12). The new drug may also be used for treatment of associated nerve pain in adults with diabetic neuropathy and postherpetic neuralgia.
The 6th Conference of Farmak School of Young Scientists was held on 1 November 2018. 130 guests and employees of Farmak JSC attended the event; 26 reports were presented. This conference already enjoys popularity among students, young scientists, and post-graduate students. The School of Young Scientists is a platform for presenting scientific achievements a...
The strategic goal of Farmak JSC is to expand exports to the EU and to enter new markets Imposition of sanctions on Farmak JSC will not affect the company’s strategy and operations. Farmak JSC represents our state with dignity in the international arena: the company’s products are marketed in more than 20 countries of the […]
Farmak JSC received a Letter of gratitude from the Chairman of Committee on Public Health of the Verkhovna Rada of Ukraine for timely assistance during the elimination of the emergency situation in Chernihiv region caused by the explosion of ammunition warehouses near the town of Ichnia. Farmak often receives letters of gratitude as it always […]